Lupin Limited share price

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron s…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty 500 Nifty Midcap 150NSE: LUPINISIN INE326A01037

16 Oct 2026, 3:28 PM IST₹1,961.60▼ 19.30 (0.97%)

Market Cap₹ 89,702 Cr.
Current Price₹ 1,961.60
High / Low₹ 2,530 / 1,900
Stock P/E16.2
Book Value₹ 491
Dividend Yield0.91 %
ROCE28.3 %
ROE26.90 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 120.73
Price / Book3.99
OPM24.8 %
Debt / Equity0.29
Sales growth (5Y)13.0 %
Profit growth (5Y)34.3 %
Promoter holding47.0 %
EV / EBITDA10.2
Beta0.17
All-time high₹ 2,530

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
LUPIN	-4.08%	-21.55%	-15.70%	-7.01%	+0.53%	+17.85%	+15.96%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Lupin Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹89,702 crore.
It trades at 16.2 times its last 12 months' earnings and 4.0 times book value.
Revenue grew 13.0% a year over the last 5 years, profit 34.3% a year.
Return on equity was 26.9% and return on capital employed 28.3% in the latest year.
Debt was 0.29 times shareholders' equity.
The share price is 22.5% below its 52-week high and up 0.5% over one year.
Promoters and insiders hold about 47.0%; institutions about 35.1%.

Pros

Strong return on equity: 20.7% on average over the last 3 years.
Profit has grown 34.3% a year over the last 5 years.
Latest quarter (Jun 2026): sales up 32% and profit up 16% from a year ago.
Trades at 16.2 times earnings, below its 3-year median of 31.3.
Borrowings are moderate at 0.29 times shareholders' equity.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Lupin Limited

Employees: 26,021
Head office: Mumbai
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty 500 Nifty Midcap 150

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Lupin	1,961.60	16.2	89,702	0.91	1,417	16.01	8,277	32.04	28.3	26.9	3.99	24.8	0.29	47.02	27,958	13.0
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 60 Co.	1,860.20	34.1	11,251	0.18	844	15.15	7,461	18.81	16.4	12.9	3.99	15.2	0.25	53.40	27,339	11.2

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	4,814	5,039	5,197	4,961	5,600	5,673	5,768	5,667	6,268	7,048	7,168	7,475	8,277
YOY Sales Growth %		21.54%	20.25%	11.98%	16.33%	12.59%	10.97%	14.24%	11.93%	24.23%	24.27%	31.89%	32.04%
	3,958	4,121	4,159	3,964	4,359	4,332	4,412	4,346	4,541	4,706	4,906	4,989	5,827
Material Cost %	34%	34%	33%	32%	31%	30%	30%	30%	28%	26%	26%	25%	25%
Employee Cost %	18%	17%	17%	18%	17%	18%	17%	18%	17%	16%	16%	17%	17%
Other Expenses %	31%	31%	30%	30%	29%	29%	30%	29%	27%	25%	26%	25%	28%
Operating Profit	856	918	1,038	997	1,241	1,340	1,356	1,321	1,727	2,341	2,262	2,486	2,450
OPM %	18%	18%	20%	20%	22%	24%	24%	23%	28%	33%	32%	33%	30%
	23	40	29	29	68	42	54	57	79	90	115	141	130
Exceptional items											-427	-131
Interest	86	81	74	71	68	71	67	89	92	108	115	120	110
Depreciation	235	248	257	457	248	257	271	393	299	317	313	447	453
Profit before tax	559	630	736	498	993	1,055	1,071	896	1,416	2,007	1,522	1,928	2,017
	19%	21%	16%	26%	19%	19%	20%	13%	14%	26%	22%	24%	30%
Current tax	130	172	226	106	238	203	269	281	491	324	205	508	984
Deferred tax	-25	-38	-108	23	-50	-8	-57	-168	-297	198	137	-49	-384
	453	495	619	368	806	859	859	782	1,221	1,485	1,181	1,469	1,417
Profit from associates													-0
Minority share	1	6	6	9	4	7	4	10	2	7	5	8	2
Profit to shareholders	452	490	613	359	801	853	855	773	1,219	1,478	1,176	1,460	1,415
YOY Profit Growth %		268.35%	292.45%	51.91%	77.69%	73.52%	38.82%	112.48%	51.63%	72.76%	37.45%	87.72%	16.01%
EPS in Rs	9.94	10.76	13.47	7.89	17.58	18.70	18.75	16.93	26.70	32.36	25.74	31.96	30.95
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	3,496	3,659	4,116	3,396	4,168	4,106	4,208	4,486	5,709	4,068	4,501	5,235	7,172
YOY Sales Growth %	27.93%	29.35%	43.85%	19.73%	19.22%	12.21%	2.24%	32.09%	36.97%	-0.92%	6.97%	16.70%	25.63%
	2,791	2,824	2,898	2,696	2,968	2,991	2,797	2,740	2,979	2,893	2,885	2,953	3,439
Material Cost %	36%	34%	32%	36%	30%	32%	27%	26%	21%	31%	26%	24%	19%
Employee Cost %	15%	15%	13%	15%	14%	14%	14%	12%	11%	15%	14%	13%	10%
Other Expenses %	29%	29%	25%	28%	27%	26%	25%	23%	20%	25%	24%	20%	19%
Operating Profit	705	835	1,217	700	1,200	1,115	1,411	1,746	2,730	1,176	1,617	2,282	3,733
OPM %	20%	23%	30%	21%	29%	27%	34%	39%	48%	29%	36%	44%	52%
	28	26	23	31	38	33	55	49	54	70	100	89	102
Exceptional items							-77			593	-634	448
Interest	16	15	11	13	14	18	20	34	19	28	36	39	36
Depreciation	140	149	145	290	141	146	153	208	177	175	179	177	190
Profit before tax	577	696	1,084	428	1,083	984	1,217	1,553	2,588	1,636	868	2,602	3,610
	17%	21%	15%	10%	18%	18%	19%	17%	18%	17%	17%	17%	25%
Current tax	101	130	185	69	189	172	226	270	452	287	141	471	893
Deferred tax	-1	18	-17	-25	5	4	7	-9	9	-9	9	-32	3
	477	549	916	384	889	808	985	1,291	2,128	1,357	717	2,164	2,715
YOY Profit Growth %	307.03%	269.14%	2,168.42%	222.73%	86.43%	47.24%	7.45%	236.22%	139.33%	68.04%	-27.14%	67.55%	27.56%
EPS in Rs	10.48	12.06	20.14	8.43	19.51	17.71	21.58	28.30	46.60	29.72	15.71	47.35	59.37
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	15,560	16,369	15,375	15,163	16,405	16,642	20,011	22,708	27,958	29,967
YOY Sales Growth %		5.20%	-6.08%	-1.38%	8.19%	1.44%	20.25%	13.48%	23.12%
	12,657	13,836	13,020	12,596	16,118	14,844	16,200	17,425	19,142	20,428
Material Cost %	34%	36%	35%	35%	40%	41%	33%	30%	26%	26%
Employee Cost %	18%	19%	19%	19%	18%	19%	17%	17%	16%	16%
Other Expenses %	29%	30%	30%	29%	41%	30%	30%	29%	26%	26%
Operating Profit	2,903	2,533	2,355	2,567	287	1,798	3,811	5,283	8,816	9,538
OPM %	19%	15%	15%	17%	2%	11%	19%	23%	32%	32%
	395	713	484	136	142	73	120	196	424	476
Exceptional items	-1,464	-336	-752						-558	-558
Interest	204	308	363	141	143	274	312	295	434	452
Depreciation	1,086	1,085	970	887	1,659	881	1,197	1,169	1,376	1,529
Profit before tax	543	1,517	753	1,675	-1,373	716	2,422	4,015	6,873	7,474
	53%	59%	154%	27%		38%	20%	18%	22%	26%
Current tax	535	873	687	438	161	246	634	991	1,527
Deferred tax	-247	29	470	10	-24	22	-147	-282	-10
	258	615	-270	1,228	-1,509	448	1,936	3,306	5,355	5,551
Profit from associates	4		4	1	0					-0
Minority share	7	9	3	11	19	18	21	25	23	22
Profit to shareholders	251	607	-611	1,217	-1,528	430	1,914	3,282	5,333	5,529
YOY Profit Growth %		138.23%	-143.83%		-222.92%		332.35%	70.82%	61.98%
EPS in Rs	30.83	34.34	-5.96	27.09	-33.65	9.46	42.05	71.95	116.75	121.01
Dividend Payout %						42%	10%	11%	10%

Compounded Sales Growth

5 Years:: 13%
3 Years:: 19%
TTM:: 28%

Compounded Profit Growth

5 Years:: 34%
3 Years:: 129%
TTM:: 49%

Stock Price CAGR

5 Years:: 16%
3 Years:: 18%
1 Year:: 1%

Return on Equity

4 Years:: 16%
Last Year:: 27%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	9,854	11,032	11,026	11,056	11,772	11,259	14,667	16,968	19,513	20,976
YOY Sales Growth %		11.95%	-0.05%	0.27%	6.47%	-4.36%	30.27%	15.69%	15.00%
	8,002	8,504	9,118	9,012	11,496	10,176	11,207	11,495	11,709	12,169
Material Cost %	35%	35%	38%	38%	38%	43%	34%	29%	25%	24%
Employee Cost %	15%	14%	15%	15%	16%	17%	14%	14%	13%	12%
Other Expenses %	31%	28%	29%	28%	43%	31%	28%	25%	22%	21%
Operating Profit	1,852	2,528	1,908	2,044	276	1,083	3,459	5,472	7,804	8,807
OPM %	19%	23%	17%	18%	2%	10%	24%	32%	40%	42%
	365	616	475	129	150	91	107	174	313	361
Exceptional items		-340	-759					-77	407	407
Interest	33	35	53	41	73	98	56	85	121	138
Depreciation	390	426	519	503	514	548	725	648	707	720
Profit before tax	1,794	2,342	1,052	1,630	-162	527	2,785	4,837	7,694	8,716
	25%	34%	31%	23%		19%	16%	18%	17%	20%
Current tax	387	795	362	363	58	96	484	857	1,351
Deferred tax	63	9	-37	8	-31	6	-25	7	-24
	1,345	1,539	728	1,259	-189	425	2,326	3,973	6,367	6,953
YOY Profit Growth %		14.44%	-52.72%	72.99%	-114.99%		447.04%	70.80%	60.25%
EPS in Rs	29.76	75.57	16.07	27.77	-4.16	9.35	51.10	87.10	139.38	152.15
Dividend Payout %						43%	8%	9%	9%

Compounded Sales Growth

5 Years:: 12%
3 Years:: 20%
TTM:: 13%

Compounded Profit Growth

5 Years:: 38%
3 Years:: 146%
TTM:: 33%

Stock Price CAGR

5 Years:: 16%
3 Years:: 18%
1 Year:: 1%

Return on Equity

4 Years:: 16%
Last Year:: 27%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	91	91	91	91
Reserves	12,374	14,199	17,112	22,357
	4,542	2,922	5,448	6,616
Long term borrowings	28		1,766	1,643
Short term borrowings	4,217	2,670	3,310	4,267
	5,950	6,785	6,554	9,300
Trade payables	2,532	2,958	2,958	4,173
Minority interest	78	83	91	65
Current liabilities	9,265	8,502	8,961	12,651
Total Liabilities	22,956	23,997	29,205	38,365
	5,678	5,561	5,614	6,255
Gross block	9,716	10,133	10,563	11,778
Accumulated depreciation	4,039	4,572	4,949	5,523
Goodwill & intangibles	4,053	4,157	4,732	5,866
CWIP	1,033	662	465	806
	16,246	17,774	23,126	31,304
Inventories	4,492	4,954	5,476	6,083
Trade receivables	4,481	4,692	5,497	6,604
Cash & equivalents	1,232	983	1,544	4,168
Current assets	12,451	13,448	16,799	24,027
Total Assets	22,956	23,997	29,205	38,365

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,897	3,648	3,000	7,335
Profit for the year	430	1,914	3,282	5,333
Working capital changes	327	86	-1,411	634
Direct taxes paid	-243	-326	-906	-1,267
	-1,287	-1,712	-4,172	-3,865
Fixed assets purchased	-1,500	-929	-1,682	-2,055
Fixed assets sold	39	12	29	248
Investments purchased	-11,823	-11,128	-17,048	-18,847
Investments sold	12,256	10,591	17,016	16,466
	-337	-2,184	1,732	-846
Proceeds from borrowings			1,221
Repayment of borrowings	-113	-28
Interest paid	-227	-283	-255	-400
Dividends paid	-183	-183	-365	-548
Net Cash Flow	273	-248	560	2,624
Free Cash Flow	398	2,719	1,318	5,280

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	3.5%	14.3%	20.8%	26.9%
ROCE	7.0%	17.4%	21.2%	28.3%
Operating margin	5.5%	14.2%	19.6%	24.8%
Net margin	2.6%	9.7%	14.8%	19.4%
Debt / equity	0.36	0.20	0.32	0.29
Current ratio	1.34	1.58	1.87	1.90
Debtor days	101	87	90	88
Inventory days	226	253	268	274
Days payable	127	151	145	188
Cash conversion cycle	200	189	213	174
Working capital days	71	92	129	151

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 46.85%
FIIs 22.42%
DIIs 24.65%
Public 6.08%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	47.06%	47.04%	47.01%	46.98%	46.96%	46.95%	46.92%	46.90%	46.90%	46.89%	46.86%	46.85%
	14.99%	16.11%	18.28%	19.32%	21.50%	22.04%	21.46%	21.25%	20.49%	21.49%	21.71%	22.42%
Foreign portfolio investors (Cat. I)	14.46%	15.58%	17.70%	18.66%	20.64%	21.21%	20.62%	20.49%	19.75%	20.76%	20.96%	21.73%
Foreign portfolio investors (Cat. II)	0.53%	0.53%	0.59%	0.66%	0.86%	0.83%	0.84%	0.76%	0.75%	0.74%	0.74%	0.69%
	29.42%	29.73%	27.76%	26.78%	25.09%	24.74%	25.41%	25.56%	26.55%	25.58%	25.32%	24.65%
Mutual funds	16.71%	18.92%	16.82%	16.23%	16.89%	16.92%	17.55%	19.35%	20.57%	18.01%	16.93%	14.84%
Insurance companies	12.26%	9.70%	9.95%	9.41%	7.20%	6.41%	6.34%	4.64%	4.44%	5.59%	6.12%	6.93%
Banks	0.14%	0.14%	0.07%	0.15%	0.04%				0.04%			0.05%
Provident & pension funds		0.93%	0.86%	0.95%	0.94%	1.31%	1.42%	1.48%	1.47%	1.94%	2.22%	2.75%
Alternative investment funds	0.03%	0.03%	0.06%	0.03%	0.03%	0.09%	0.10%	0.08%	0.04%	0.04%	0.05%	0.08%
Government	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
	8.52%	7.11%	6.93%	6.92%	6.44%	6.26%	6.20%	6.28%	6.06%	6.03%	6.11%	6.08%
Retail (up to ₹2 lakh)	6.15%	5.79%	5.62%	5.57%	5.23%	5.11%	5.04%	5.15%	4.98%	4.96%	4.92%	4.92%
HNIs (above ₹2 lakh)	0.09%	0.08%	0.08%	0.08%	0.06%	0.06%	0.06%	0.08%	0.14%	0.14%	0.14%	0.14%
NRIs	0.36%	0.34%	0.35%	0.32%	0.32%	0.30%	0.31%	0.29%	0.29%	0.29%	0.31%	0.29%
Bodies corporate	0.41%	0.40%	0.39%	0.31%	0.32%	0.30%	0.30%	0.28%	0.24%	0.24%	0.26%	0.34%
IEPF	0.17%	0.17%	0.17%	0.17%	0.16%	0.17%	0.17%	0.17%	0.17%	0.18%	0.18%	0.17%
No. of Shareholders	2,89,074	2,81,542	2,80,248	2,88,537	2,79,280	2,81,988	2,83,210	2,86,604	2,80,256	2,88,931	2,90,411	3,00,283

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Lupin

Holder (above 1%)	Stake
HDFC Balanced Advantage FundMutual fund	4.37%
Life Insurance Corporation Of IndiaInsurance	4.09%
Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier IPension fund	2.75%
Nippon India Growth Mid Cap FundMutual fund	2.60%
SBI ELSS Tax Saver FundMutual fund	1.96%
Mirae Asset Large & Midcap FundMutual fund	1.74%
Hdfc Life Insurance Company LimitedInsurance	1.10%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 14.84% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 5 Nov 2026
Ex-dividend date: 17 Jul 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Lupin Limited

What is the share price of Lupin Limited today?

Lupin Limited (LUPIN) last traded at ₹1,961.60 on NSE (16 Oct 2026, 3:28 PM IST). Prices may be delayed.

What is the market cap of Lupin Limited?

About ₹89,702 crore at the latest price.

What is the P/E ratio of Lupin Limited?

About 16.2 times its earnings over the last 12 months.

Is Lupin Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Lupin Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Lupin Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Lupin Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Lupin

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Lupin Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next